We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A patient received the first implant earlier this month of an absorbable drug-eluting stent as part of a clinical trial conducted in Auckland City Hospital in New Zealand.
Neuromuscular electronic stimulation (NMES) can give stroke patients enough active wrist extension to qualify for physical therapy, according to researchers from the University of Cincinnati College of Medicine.
Angioplasty with coronary drug-eluting stent therapy may be a viable alternative treatment to more complicated bypass surgery for patients with left main coronary artery (LMCA) disease, according to a new study conducted at Cedars-Sinai Medical Center.
The Merci Retriever, the only medical device cleared by the FDA to remove clots from the brain during an ischemic stroke, restored blood flow in nearly 70 percent of stroke patients, according to a new study.
Drug treatments administered prior to emergency heart attack surgery may do more harm than good, according to a study recently published in a major journal.
This month, the NIH launches a partnership with medical-imaging and pharmaceutical companies to identify biological markers of memory decline related to Alzheimer’s disease.
Texas-based LDR Spine received an investigational device exemption (IDE) from the FDA to conduct clinical trials with its Mobi-C artificial cervical disc, the company announced Feb. 1.
Cordis’ Cypher sirolimus-eluting coronary stent may reduce reblockage (restenosis) and the occurrence of major adverse cardiac events in patients with complex coronary artery lesions without increasing the risk of blood clots (thrombosis), according to a new study published in the Journal of the American College of Cardiology.
Using a pacemaker to accelerate the heart rate during sleep has no significant effect in treating patients with sleep apnea, according to a new study that contradicts earlier findings on the role of atrial overdrive pacing (AOP) in treating this common condition.
Bristol-Myers Squibb (BMS) has reached an agreement with Merck to end the collaborative development of the investigational oral diabetes drug Pargluva.